The article discusses chronic thromboembolic pulmonary hypertension (CTEPH), a condition where chronic thromboembolic involvement of the pulmonary vascular bed leads to pulmonary hypertension and right heart dysfunction. The authors highlight the potential curability of CTEPH with surgical endarterectomy, which has seen increased recognition and improved surgical techniques over the past decades. They also emphasize the importance of pulmonary hypertensive-specific medical therapy for patients with surgically inaccessible disease. However, the underappreciation of CTEPH and misinterpretation of diagnostic information can lead to inappropriate exclusion from surgical consideration, potentially resulting in the prescription of pulmonary hypertensive medications. The article provides an overview of the diagnosis, treatment, and management of CTEPH, including the use of anticoagulation, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and prostanoids. It also discusses the role of pulmonary thromboendarterectomy (PEA) as the preferred treatment for selected patients, along with postoperative complications and mortality rates. The authors emphasize the need for multidisciplinary care and referral to specialized centers for optimal management.The article discusses chronic thromboembolic pulmonary hypertension (CTEPH), a condition where chronic thromboembolic involvement of the pulmonary vascular bed leads to pulmonary hypertension and right heart dysfunction. The authors highlight the potential curability of CTEPH with surgical endarterectomy, which has seen increased recognition and improved surgical techniques over the past decades. They also emphasize the importance of pulmonary hypertensive-specific medical therapy for patients with surgically inaccessible disease. However, the underappreciation of CTEPH and misinterpretation of diagnostic information can lead to inappropriate exclusion from surgical consideration, potentially resulting in the prescription of pulmonary hypertensive medications. The article provides an overview of the diagnosis, treatment, and management of CTEPH, including the use of anticoagulation, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and prostanoids. It also discusses the role of pulmonary thromboendarterectomy (PEA) as the preferred treatment for selected patients, along with postoperative complications and mortality rates. The authors emphasize the need for multidisciplinary care and referral to specialized centers for optimal management.